Since CSC also overexpresses HER2 even in breast cancers not categorized as HER2-positive, HER2-directed treatments using Herceptin® (trastuzumab) are indicated for numerous patients with both HER2-positive and HER2-negative breast cancer [25]. Here, ERBB2 is linked to breast carcinoma.